Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies

Next Previous
Trial Profile

A Modular Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ceralasertib in Combination With Cytotoxic Chemotherapy and/or DNA Damage Repair/Novel Anti-cancer Agents in Patients With Advanced Solid Malignancies

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ceralasertib (Primary) ; Carboplatin; Durvalumab; Olaparib
  • Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; HER2 negative breast cancer; Lung cancer; Male breast cancer; Mesothelioma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AstraZeneca

Most Recent Events

  • 18 Mar 2025 Planned End Date changed from 18 Mar 2025 to 31 Dec 2025.
  • 18 Mar 2025 Status changed from recruiting to active, no longer recruiting.
  • 04 Oct 2024 Planned End Date changed from 15 Jul 2026 to 18 Mar 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top